SILENCE THERAPEUTICS PLC-ADR (SLN) Forecast, Price Target & Analyst Ratings
NASDAQ:SLN • US82686Q1013
Current stock price
6.38 USD
-0.25 (-3.77%)
At close:
6.26 USD
-0.12 (-1.88%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SILENCE THERAPEUTICS PLC-ADR (SLN).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $6.38 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
SLN was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about SLN.
In the previous month the buy percentage consensus was at a similar level.
SLN was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-05-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-03-04 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-02-11 | Goldman Sachs | Initiate | Sell |
| 2025-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-08 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2024-08-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 244K | 5.479M 2,145.49% | 10.128M 84.86% | 24.617M 143.05% | 30.798M 25.11% | 15.779M -48.77% | 32.344M 104.98% | |
| EBITDA YoY % growth | -20.172M -44.52% | -22.252M -10.31% | -35.351M -58.87% | N/A | N/A | -64.062M | -75.086M -17.21% | -39.729M 47.09% | |
| EBIT YoY % growth | -20.571M -42.94% | -22.734M -10.51% | -35.847M -57.68% | N/A | -44.262M | -57.936M -30.89% | -80.063M -38.19% | -81.406M -1.68% | |
| Operating Margin | N/A | -9,317.21% | -654.26% | N/A | -179.80% | -188.12% | -507.40% | -251.69% | |
| EPS YoY % growth | N/A | N/A -20,270.00% | -0.40 -89.69% | -0.50 -24.74% | -0.62 -25.00% | -0.33 46.06% | -0.36 -7.31% | -0.40 -10.53% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A